-
Although the currently available COVID-19 vaccines are highly effective, limited manufacturing capacity and the need for cold-chain storage hinder their global distribution.
-
A recent study tested the efficacy of a new adeno-associated virus (AAV) vector-based vaccine in mice and macaques.
-
A single dose of the AAV-based vaccine provided protection against SARS-CoV-2 infection in macaques and elicited a potent immune response against the virus for at least 11 months.
-
The vaccine was stable at room temperature for 1 month and could potentially be manufactured on a large scale using established processes.

COVID-19: Experimental vaccine lasts 1 month at room temperature
previous post